- Conditions
- Head and Neck Neoplasms
- Interventions
- Placebo, Afatinib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Orange, California • Aurora, Colorado + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 673
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic, Diabetes Mellitus
- Interventions
- Empagliflozin 10 MG
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Asthma
- Interventions
- Placebo twice daily, Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily, Olodaterol high daily dose once daily and placebo, Olodaterol medium daily dose once daily and placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 12
- States / cities
- Huntington Beach, California • Centennial, Colorado • Wheat Ridge, Colorado + 9 more
- Conditions
- HIV Infections
- Interventions
- Nevirapine, Lamivudine
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 53
- States / cities
- Montgomery, Alabama • Los Angeles, California • Palo Alto, California + 41 more
- Conditions
- Colorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma
- Interventions
- BI 765049
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 1 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Nintedanib, Pirfenidone
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 6
- States / cities
- Danbury, Connecticut • New Orleans, Louisiana • Minneapolis, Minnesota + 3 more
- Conditions
- Asthma
- Interventions
- Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palmdale, California + 36 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- tiotropium + olodaterol, tiotropium, olodaterol, Respimat
- Drug · Device
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,624 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 35
- States / cities
- Jasper, Alabama • Mobile, Alabama • Boulder, Colorado + 31 more
- Conditions
- Cystic Fibrosis
- Interventions
- BIIL 283 BS (Amelubent)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 35
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 30 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Empagliflozin, Matching placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 47
- States / cities
- Huntsville, Alabama • Mesa, Arizona • San Diego, California + 38 more
- Conditions
- Asthma
- Interventions
- Placebo, Fluticasone propionate, BI 54903
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 37
- States / cities
- Fountain Valley, California • Fullerton, California • Long Beach, California + 33 more
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- BI 1467335, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 17
- States / cities
- Coronado, California • La Jolla, California • La Mesa, California + 13 more
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD
- Interventions
- Tiotropium, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Lung Cancer, Lung Metastases
- Interventions
- Nintedanib, Prednisone, Placebo
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 12
- States / cities
- Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 9 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, BI 1356 dose 3 once daily, BI 1356 dose 2 once daily, BI 1356 dose 1 once daily, Metformin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 34
- States / cities
- Chula Vista, California • La Jolla, California • Walnut Creek, California + 30 more
- Conditions
- Systemic Sclerosis
- Interventions
- Placebo matching nerandomilast formulation 1, Placebo matching nerandomilast formulation 2, Nerandomilast formulation 1, Nerandomilast formulation 2
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more
- Conditions
- Atrial Fibrillation, Atrial Flutter
- Interventions
- dabigatran etexilate mesylate
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Schizophrenia
- Interventions
- CT-156-C-001
- Device
- Lead sponsor
- Click Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Dasatinib - 1A, Afatinib - 1A, Dasatinib - 1B, Afatinib - 1B
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Atrial Fibrillation
- Interventions
- Not listed
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25,586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
- Conditions
- Brain Cancer
- Interventions
- Afatinib
- Drug
- Lead sponsor
- Santosh Kesari
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- HIV Infections
- Interventions
- tenofovir DF 300 mg QD, emtricitabine 200 mg QD, Nevirapine 200 mg BID, Atazanavir 300 mg, Ritonavir 100 mg
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 19
- States / cities
- Beverly Hills, California • Los Angeles, California • Denver, Colorado + 15 more
- Conditions
- Schizophrenia
- Interventions
- Iclepertin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 51 Years
- Enrollment
- 1,356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 49
- States / cities
- Anaheim, California • Bellflower, California • Culver City, California + 40 more
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Rituximab, BI 695500
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 13
- States / cities
- Muscle Shoals, Alabama • Bakersfield, California • Burbank, California + 10 more